ID21676A - Identifikasi interaksi-interaksi ikatan yang khas antara antibodi-antibodi dan antigen-antigen pembantu rangsangan b7.1 dan b7.2 manusia tertentu - Google Patents

Identifikasi interaksi-interaksi ikatan yang khas antara antibodi-antibodi dan antigen-antigen pembantu rangsangan b7.1 dan b7.2 manusia tertentu

Info

Publication number
ID21676A
ID21676A IDW990357D ID990357D ID21676A ID 21676 A ID21676 A ID 21676A ID W990357 D IDW990357 D ID W990357D ID 990357 D ID990357 D ID 990357D ID 21676 A ID21676 A ID 21676A
Authority
ID
Indonesia
Prior art keywords
antibodies
specific
interactions
identification
antigents
Prior art date
Application number
IDW990357D
Other languages
English (en)
Indonesian (id)
Inventor
Darrell R Anderson
Peter Brams
Nabil Hanna
Cheryl Heard
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Publication of ID21676A publication Critical patent/ID21676A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
IDW990357D 1996-11-08 1997-10-29 Identifikasi interaksi-interaksi ikatan yang khas antara antibodi-antibodi dan antigen-antigen pembantu rangsangan b7.1 dan b7.2 manusia tertentu ID21676A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74636196A 1996-11-08 1996-11-08

Publications (1)

Publication Number Publication Date
ID21676A true ID21676A (id) 1999-07-08

Family

ID=25000516

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW990357D ID21676A (id) 1996-11-08 1997-10-29 Identifikasi interaksi-interaksi ikatan yang khas antara antibodi-antibodi dan antigen-antigen pembantu rangsangan b7.1 dan b7.2 manusia tertentu

Country Status (13)

Country Link
EP (2) EP1007090B1 (de)
JP (3) JP4048294B2 (de)
KR (1) KR100510604B1 (de)
CN (1) CN1198646C (de)
AT (1) ATE453406T1 (de)
AU (1) AU739058B2 (de)
BR (1) BR9713498A (de)
CA (1) CA2270922A1 (de)
DE (1) DE69739725D1 (de)
ID (1) ID21676A (de)
NO (1) NO992212L (de)
RU (1) RU2221590C2 (de)
WO (1) WO1998019706A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
CN1068524C (zh) * 1997-06-23 2001-07-18 叶庆炜 一种治疗顽症牛皮癣的药物
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
CN1360596A (zh) 1999-02-12 2002-07-24 遗传研究所有限公司 与b7分子发生反应的人源化免疫球蛋白及应用该免疫球蛋白的治疗方法
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
WO2001089567A1 (en) * 2000-05-22 2001-11-29 Idec Pharmaceuticals Corporation Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens
US6965018B2 (en) 2000-06-06 2005-11-15 Bristol-Myers Squibb Company Antibodies directed to B7-related polypeptide, BSL-2
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
CA2436180C (en) * 2001-01-31 2011-11-08 Idec Pharmaceutical Corporation Immunoregulatory antibodies and uses thereof
JP4212278B2 (ja) * 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
WO2003039486A2 (en) * 2001-11-09 2003-05-15 Idec Pharmaceuticals Corporation Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20040152105A1 (en) * 2002-09-06 2004-08-05 Cytos Biotechnology Ag. Immune modulatory compounds and methods
CA2574802A1 (en) * 2004-07-20 2006-02-02 Isogenis, Inc. Specific inhibition of autoimmunity and diseases associated with autoantigens
CN1817909B (zh) * 2005-02-08 2010-08-11 复旦大学 一种双功能融合蛋白
CN100369931C (zh) * 2005-04-07 2008-02-20 苏州大学 抗人b7-1分子单克隆抗体及其应用
EP3530736A3 (de) * 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Humane monoklonale antikörper für den programmierten tod 1 (pd-1) und verfahren zur behandlung von krebs mit pd-1-antikörpern allein oder in kombination mit anderen immunotherapeutika
US7510844B2 (en) * 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2011127418A1 (en) 2010-04-09 2011-10-13 Amgen Inc. Btnl9 proteins, nucleic acids, and antibodies and uses thereof
EP2804619B1 (de) * 2012-01-16 2021-10-13 Atox Bio Ltd. Reltecimod zur behandlung von bakteriellen infektionen
CZ306905B6 (cs) 2013-06-11 2017-09-06 Česká zemědělská univerzita v Praze Způsob pro stanovení vodní hodnoty sněhu sněhové vrstvy a zařízení pro provádění tohoto způsobu
CN106177931B (zh) * 2016-08-25 2018-02-02 河北浓孚雨生物科技有限公司 免疫检测点双阻断ctl高效率杀伤细胞制剂的制备方法
EP3892299A4 (de) 2018-12-07 2022-11-30 ONO Pharmaceutical Co., Ltd. Immunsuppressionsmittel

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091313A (en) * 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
DD297839A5 (de) * 1988-08-23 1992-01-23 Dana Farber Cancer Institute,Us Alpha-untereinheit des lfa-l-leukozytadhaesionsrezeptors
US6641809B1 (en) * 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
DE69226871T3 (de) * 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies

Also Published As

Publication number Publication date
BR9713498A (pt) 2000-02-29
DE69739725D1 (de) 2010-02-11
CA2270922A1 (en) 1998-05-14
EP1007090A4 (de) 2001-03-14
NO992212D0 (no) 1999-05-06
JP2007330261A (ja) 2007-12-27
JP2001504693A (ja) 2001-04-10
ATE453406T1 (de) 2010-01-15
RU2221590C2 (ru) 2004-01-20
WO1998019706A1 (en) 1998-05-14
JP4320381B2 (ja) 2009-08-26
NO992212L (no) 1999-07-08
AU5100998A (en) 1998-05-29
CN1244128A (zh) 2000-02-09
KR100510604B1 (ko) 2005-08-31
CN1198646C (zh) 2005-04-27
EP1878748A2 (de) 2008-01-16
HK1025741A1 (en) 2000-11-24
KR20000053137A (ko) 2000-08-25
EP1007090B1 (de) 2009-12-30
EP1007090A1 (de) 2000-06-14
JP4048294B2 (ja) 2008-02-20
JP2009001570A (ja) 2009-01-08
AU739058B2 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
ATE453406T1 (de) Identifikation von bindungs- interaktionen zwischen gewissen antikorpern und den humanen costimulatorischen antigenen b7.1 (cd80) und b7.2 (cd28)
PT892643E (pt) Metodos para inibir uma resposta imunitaria bloqueando os circuitos de gp39/cd40 e ctla4/cd28/b7 e composicoes utilizaveis para o efeito
Pichler et al. T cells as antigen-presenting cells
ZA986084B (en) CTL epitopes from EBV
DK0741784T3 (da) Ligand (ACT-4-L) til en receptor på overfladen af aktiverede CD4+ T-celler
NL300220I2 (nl) Immunoglobuline varianten voor specifieke FC-epsilon receptoren.
BR0116932A (pt) Artigo abrasivo, método de preparar o mesmo, artigo abrasivo não-tecido, e, método de preparar o mesmo
IL136511A0 (en) Genetically engineered mhc molecules
GB9809280D0 (en) Immunosupression
MXPA02001911A (es) Anticuerpos ctla-4 humanos y sus usos.
MX9602879A (es) Moleculas mutantes de ctla4 y usos de las mismas.
EP1194164B8 (de) Prion protein peptide und deren verwendung
FR2695563B1 (fr) Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
NO306698B1 (no) Aktivstoffplaster med kontrollert avgivelse samt fremgangsmåte for fremstilling derav
WO2000000082A8 (en) Disposable article having proactive sensor
FI954129A0 (fi) Verkkoutuvat dispersiojauheet kuitujen sideaineina
DE69942100D1 (de) Künstliche antigen-spezifischen zellen und zugehörige verfahren
PT1181319E (pt) Anticorpos quiméricos contra dr4 e suas utilizações
DE69736244D1 (de) Lösliche lymphotoxin-beta rezeptoren, anti-lymphotoxin-antikörper und anti-lymphotoxin ligand antikörper als therapeutische wirkstoffe zur behandlung von immunologischen krankheiten
ATE89852T1 (de) Verwendung von polyurethan-mischungen als klebstoffbindemittel zur verklebung von sbsblockpolymerisaten.
Dasgupta et al. Involvement of major histocompatibility complex class I antigens in T cell activation
WO2003025000A3 (en) Peptides capable of modulating immune response
Young et al. Killer cell inhibitory receptor interactions with HLA class I molecules: implications for alloreactivity and transplantation
Hämmerling et al. Cellular expression of Ia antigens and their possible role in immune reactions
Friccius et al. Induction of hyporesponsiveness in human lymphocytes-T despite their expression of both the co-receptor CD28 and its ligand B7